OncoTerra Services
Products
Access New Insights in Precision Oncology
The OncoTerra Oncology Platform leverages high-resolution genomic technology to expand the potential of precision oncology. It takes advantage of the unique properties of ultra-long-range genome sequencing to unlock the wealth of diagnostic and prognostic information contained in FFPE samples, in a cost-effective and scalable NGS-based assay.
Proximity ligation is used to trap short-, long-, and ultra-long-range intracellular DNA contacts (black arcs) in DNA extracted from solid tumor or hematological samples. Chimeric junctions originating from the same cell are recovered, converted into an Illumina® sequencing library, and subjected to paired-end sequencing. The signal increases as the genomic distance between any two loci across the genome decreases. The novel OncoTerra Oncology Platform extrapolates this unique information with a high degree of confidence, enabling the genome-wide detection of all major types of chromosomal abnormalities associated with cancer.
Download to learn more
Features and Benefits
- Genome-wide detection of chromosomal abnormalities
in a single, NGS-based assay - Comprehensive cytogenomic information from
a wide variety of sample types, including FFPE tissue - New molecular technology, no dedicated
instrumentation required - Analysis included, from sample to report
OncoTerra Workflow
The OncoTerra Platform provides a sample-to-report NGS-based cytogenomics assay that starts with a solid tumor (typically FFPE) or hematological sample, and ends with a comprehensive and actionable report in standard and sequence-based nomenclature. The entire process (depicted below) can be completed in less than a week, and is scalable to large numbers of samples.
The OncoTerra workflow, from sample to report.
A proximity ligation library is prepared from a biopsy sample. Paired-end sequencing is performed on the Illumina® platform. Fully automated, cloud-based analysis is performed with Phase Genomics’ proprietary computational tools .
The OncoTerra Platform is currently offered as a comprehensive sample-to-report service. Contact us to inquire about RUO kits compatible with existing low- and high-throughput sample processing pipelines.
Application Data
Click here for more OncoTerra applications or download the OncoTerra Applications Summary
Case study: Identification of novel AML variants undetected by traditional cytogenetics
The OncoTerra Platform was used to analyze a set of 48 samples (including peripheral leukemic blood and bone marrow biopsies) collected at the time of AML diagnosis. Variants previously observed with standard-of-care cytogenetics were confirmed and additional variants were identified. This impacted the risk stratification of 25% of the patients based on the European Leukemia Network (ELN) 2022 guidelines.1
Identify all major types of chromosomal abnormalities in clinical samples
Our proprietary chemistry for the liberation of chromatin from FFPE curls was used to process clinical FFPE samples representing a range of real-world sample types. Sequencing data were analyzed using a combination of commercially available software and our deep-learning based detector. Chromosomal abnormalities, including translocations, inversions, duplications, and deletions, were detected. These included numerous balanced rearrangements that would not have been detected with chromosomal microarrays (CMA). Our method for preparing libraries for ultra-long-range sequencing does not require the use of harsh organic solvents and is compatible with plate-based processing of FFPE samples. This enables automation with liquid handlers to increase throughput, and improve process control.
Data generated in collaboration with a leading university cytogenomics laboratory.
Support & Resources
Frequently Asked Questions
Watch to learn more